Plasminogen activator inhibitor-1 and tissue-plasminogen activator in minority adolescents with type 2 diabetes and obesity

Pediatric Research

Volumn 58, Issue 3, 2005, Pages 483-487

  Umpaichitra, Vatcharapan ^a   Hussain, M Mahmood ^b   Castells, Salvador ^a  

^a BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADOLESCENT; AGE; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; ENZYME ACTIVITY; FEMALE; FIBRINOLYSIS; GENDER; GLUCOSE BLOOD LEVEL; HEMOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID DIET; MALE; MINORITY GROUP; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SEXUAL MATURATION;

ADOLESCENT; AREA UNDER CURVE; BODY MASS INDEX; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FASTING; HUMANS; MINORITY GROUPS; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; POSTPRANDIAL PERIOD; TISSUE PLASMINOGEN ACTIVATOR;

EID: 24344486790     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/01.PDR.0000164307.92308.09     Document Type: Article

References (57)

1. American Diabetes Association 2003 Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26(suppl 1):S5-S20
2. Reusch JE 2002 Current concepts in insuiin resistance, type 2 diabetes mellitus, and the metabolic syndrome. Am J Cardiol 90:19G-26G
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D 1993 Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444
4. Eckel RH, Krauss RM 1998 American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation 97:2099-2100
5. American Association of Clinical Endocrinologists (AACE) 2000 AACE medical guideline for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis. Endocr Pract 6:162-213
6. Kohler HP, Grant PJ 2000 Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342:1792-1801
7. Sowers JR, Lester MA 1999 Diabetes and cardiovascular disease. Diabetes Care 22(suppl 3):C14-C20
8. Auwerx J, Bouillon R, Collen D, Geboers J 1988 Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 8:68-72
9. Jokl R, Laimins M, Klein RL, Lyons TJ, Lopes-Virella MF, Colwell JA 1994 Platelet plasminogen activator I in patients with type II diabetes. Diabetes Care 17:818-823
10. Zeitler P, Thiede A, Muller HL 2001 Prospective study on plasma clotting parameters in diabetic children-no evidence for specific changes in coagulation system. Exp Clin Endocrinol Diabetes 109:146-150
11. Sudi KM, Gallistl S, Weinhandl G, Muntean W, Borkenstein MH 2000 Relationship between plasminogen activator inhibitor-1 antigen, leptin, and fat mass in obese children and adolescents. Metabolism 49:890-895
12. Lapolla A, Piarulli F, Sartore G, Rossetti C, Martana L, Carraro P, De Paoli M, Fedele D 2003 Peripheral artery disease in type 2 diabetes: the role of fibrinolysis. Thromb Haemost 89:91-96
13. Valle M, Gascon F, Martos R, Ruz FJ, Bermudo F, Rios R, Canete R 2000 Infantile obesity: a situation of atherothrombotic risk? Metabolism 49:672-675
14. Colwell JA 2000 Altered platelet function and fibrinolysis in diabetes mellitus. Endotrends 7:5-8
15. Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P 1989 Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients-relationship with plasma insulin. Thromb Haemost 61:370-373
16. Rosito GA, D'Agostino RB, Massaro J, Lipinska I, Mittleman MA, Sutherland P, Wilson PW, Levy D, Muller JE, Tofler GH 2004 Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost 91:683-689
17. Hernandez C, Chacon P, Garcia-Pascual L, Mesa J, Simo R 2000 Relationship between lipoprotein(a) phenotypes and plasminogen activator inhibitor type 1 in diabetic patients. Thromb Res 99:119-127
18. Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, Atlan C 1987 Relationships between plasma insulin, triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabetes Metab 13:331-336
19. Glowinska B, Urban M, Koput A, Galar M 2003 New atherosclerosis risk factors in obese, hypertensive and diabetic children and adolescents. Atherosclerosis 167:275-286
20. Cavallero E, Dachet C, Assadolahi F, Martin C, Navarro N, Ansquer JC, Corda C, Foucher C, Juhan-Vague I, Jacotot B 2002 Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control. Atherosclerosis 166:151-161
21. Romano M, Pomilio M, Vigneri S, Falco A, Chiesa PL, Chiarelli F, Davi G 2001 Endothelial perturbation in children and adolescents with type 1 diabetes: association with markers of the inflammatory reaction. Diabetes Care 24:1674-1678
22. Matsuo T, Kadowaki S, Okada K, Matsuo O 1990 Activity of tissue plasminogen activator and plasminogen activator inhibitor in noninsulin-dependent diabetes mellitus. J Diabet Complications 4:119-121
23. Ebbeling CB, Pawlak DB, Ludwig DS 2002 Childhood obesity: public-health crisis, common sense cure. Lancet 360:473-482
24. Ogden CL, Flegal KM, Carroll MD, Johnson CL 2002 Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA 288:1728-1732
25. List JF, Levitsky LL 2002 The epidemic of type 2 diabetes in children and adolescents. Endocrinol Rounds 1:
26. Berenson GS, Wattigney WA, Tracy RE, Newman WP 3rd, Srinivasan SR, Webber LS, Dalferes ER Jr, Strong JP 1992 Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogulusa Heart Study). Am J Cardiol 70:851-858
27. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group 1990 Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. JAMA 264:3018-3024
28. Jones DR 2001 A Guide to Nutrition and Dietary Exchange Values for Fast-Food. Frankling Publishing Incorporated, Indianapolis, pp 75-78
29. Diabetes Control and Complication Trial 1986 Design and methodologic considerations for the feasibility phase. Diabetes 35:530-545
30. Patsch JR, Karlin JB, Scott LW, Smith LC, Gotto AM Jr 1983 Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postprandial lipemia. Proc Natl Acad Sci USA 80:1449-1453
31. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC 1974 Enzymatic determination of total serum cholesterol. Clin Chem 20:470-475
32. Spayd RW, Bruschi B, Burdick BA, Dappen GM, Eikenberry JN, Esders TW, Figueras J, Goodhue CT, LaRossa DD, Nelson RW, Rand RN, Wu TW 1978 Multilayer film elements for clinical analysis. Clin Chem 24:1348-1350
33. +2 precipitation procedure for quantitation of high-density lipoprotein cholesterol. Select Methods Clin Chem 10:91-99
34. Friedewald WT, Levy RI, Fredrickson DS 1972 Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
35. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
36. Bastard JP, Pieroni L, Hainque B 2000 Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab Res Rev 16:192-201
37. Lewis GF, O'Meara NM, Soltys PA, Blackman JD, Iverius PH, Pugh WL, Getz GS, Polonsky KS 1991 Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. J Clin Endocrinol Metab 72:934-944
38. Moreno LA, Quintela I, Fleta J, Sarria A, Roda L, Giner A, Bueno M 2001 Postprandial triglyceridemia in obese and non-obese adolescents. Importance of body composition and fat distribution. J Pediatr Endocrinol Metab 14:193-202
39. Byrne CD, Wareham NJ, Martensz ND, Humphries SE, Metcalfe JC, Grainger DJ 1998 Increased PAI activity and PAI-1 antigen occurring with an oral fat load: associations with PAI-1 genotype and plasma active TGF-β levels. Atherosclerosis 140:45-53
40. Umpaichitra V, Banerji MA, Castells S 2004 Postprandial hyperlipidemia after a fat loading test in minority adolescents with type 2 diabetes mellitus and obesity. J Pediatr Endocrinol Metab 17:853-864
41. Chadarevian R, Bruckert E, Dejager S, Presberg P, Turpin G 1999 Relationship between triglycerides and factor VIIc and plasminogen activator inhibitor type-1: lack of threshold value. Thromb Res 96:175-182
42. Tholstrup T, Marckmann P, Hermansen J, Holmer G, Sandstrom B 1999 Effect of modified dairy fat on fasting and postprandial haemostatic variables in healthy young men. Br J Nutr 82:105-113
43. Tholstrup T, Miller GJ, Bysted A, Sanstrom B 2003 Effect of individual dietary fatty acids on postprandial activation of blood coagulation factor VII and fibrinolysis in healthy young men. Am J Clin Nutr 77:1125-1132
44. Sanders TA, de Grassi T, Acharya J, Miller GJ, Humphries SE 2004 Postprandial variations in fibrinolytic activity in middle-aged men are modulated by plasminogen activator inhibitor I 4G-675/5G genotype but not by the fat content of a meal. Am J Clin Nutr 79:577-581
45. Salomaa V, Rasi V, Pekkanen J, Jauhiainen M, Vahtera E, Pietinen P, Korhonen H, Kuulasmaa K, Ehnholm C 1993 The effects of saturated fat and n-6 polyunsaturated fat on post prandial lipemia and hemostatic activity. Atherosclerosis 103:1-11
46. Tholstrup T, Andreasen K, Sandstrom B 1996 Acute effect of high-fat meals rich in either stearic or myristic acid on hemostatic factors in healthy young men. Am J Clin Nutr 64:168-176
47. Nordoy A, Bonaa KH, Sandset PM, Hansen JB, Nilsen H 2000 Effect of ω-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia. Arterioscler Thromb Vasc Biol 20:259-265
48. Andreotti F, Davies GJ, Hackett DR, Khan MI, De Bart AC, Aber VR, Maseri A, Kluft C 1988 Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol 62:635-637
49. Wiman B, Hamsten A 1990 The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Haemost 16:207-216
50. Potter Van Loon BJ, de Bart AC, Radder JK, Frouch M, Kluft C, Menders AE 1990 Acute exogenous hyperinsulinemia does not result in elevation of plasma plasminogen activator inhibitor 1 (PAI-1) in human. Fibrinolysis 4:93-94
51. Calles-Escandon J, Mirza SA, Sobel BE, Schneider DJ 1998 Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 47:290-293
52. Mertens I, Van der Planken M, Corthouts B, Wauters M, Peiffer F, De Leeuw I, Van Gaal L 2001 Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women. Horm Metab Res 33:602-607
53. Giltay EJ, Elbers JM, Gooren LJ, Emeis JJ, Kooistra T, Asscheman H, Stehouwer CD 1998 Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women: modulation by cross-sex hormone administration. Arterioscler Thromb Vasc Biol 18:1716-1722
54. Aso Y, Matsumoto S, Fujiwara Y, Tayama K, Inukai T, Takemura Y 2002 Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1. Metabolism 51:471-476
55. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I 1997 Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 46:860-867
56. Zhang J, Ren S, Shen GX 2000 Glycation amplifies lipoprotein(a)-induced alterations in the generation of fibrinolytic regulators from human vascular endothelial cells. Atherosclerosis 150:299-308
57. Ito Y, Okeda T, Sato Y, Ito M, Sakata T 1996 Plasminogen activator inhibitor-1 in nonobese subjects with non-insulin-dependent diabetes mellitus. Proc Soc Exp Biol Med 211:287-291